

University of Groningen

## A proteomic approach for leukemia epigenetics research

van Dijk, Anneke Dirkje

DOI:  
[10.33612/diss.183763111](https://doi.org/10.33612/diss.183763111)

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*  
Publisher's PDF, also known as Version of record

*Publication date:*  
2021

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*  
van Dijk, A. D. (2021). *A proteomic approach for leukemia epigenetics research: target identification, prognostication and therapeutic guidance*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen. <https://doi.org/10.33612/diss.183763111>

### Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

### Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

# **A PROTEOMIC APPROACH FOR LEUKEMIA EPIGENETICS RESEARCH**

**Target identification, prognostication  
and therapeutic guidance**

Anneke D. van Dijk

**ISBN:** 978-94-6416-846-4

**Thesis Design:** A.D. van Dijk

**Lay-out:** Publiss | [www.publiss.nl](http://www.publiss.nl)

**Print:** Ridderprint | [www.ridderprint.nl](http://www.ridderprint.nl)

**Copyright** © 2021 A.D. van Dijk, Groningen, the Netherlands

All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system, or transmitted in any form or by any means (electronic, mechanically, photocopying, recording or otherwise), without the permission of the author, and when appropriate the publisher holding the copyrights of the published articles.



university of  
 groningen

# **A PROTEOMIC APPROACH FOR LEUKEMIA EPIGENETICS RESEARCH**

## **Target identification, prognostication and therapeutic guidance**

**PhD thesis**

to obtain the degree of PhD at the  
University of Groningen  
on the authority of the  
Rector Magnificus Prof. C. Wijmenga  
and in accordance with  
the decision by the College of Deans.

This thesis will be defended in public on  
Monday 15 November 2021 at 16.15 hours

by

**Anneke Dirkje van Dijk**

born on 19 November 1993  
in Harderwijk

**Supervisors**

Prof. G. de Haan

Prof. S.M. Kornblau

Prof. E.S.J.M. de Bont

**Co-supervisor**

Dr. S.W.M. Bruggeman

**Assessment Committee**

Prof. M.A.T.M. van Vugt

Prof. G.J.L. Kaspers

Prof. G. Garcia-Manera

**Paranymphs**

Evelien M. Bourguignon

Eva I. van Dijk



I will remember that there is art to medicine as well as science, and that warmth, sympathy, and understanding may outweigh the surgeon's knife or the chemist's drug.

Hippocratic Oath





# Table of contents

<b>Chapter 1</b>	General introduction and scope of the thesis	11
<b>Chapter 2</b>	Histone modification patterns using RPPA-based profiling predict outcome in acute myeloid leukemia patients. <i>Proteomics. 2018;18(8)</i>	35
<b>Chapter 3</b>	Loss of H3K27 methylation identifies poor outcomes in adult-onset acute leukemia. <i>Clin. Epigenetics. 2021;13(1)</i>	65
<b>Chapter 4</b>	Chromatin Profiles are Prognostic of Clinical Response to Bortezomib-Containing Chemotherapy in Pediatric Acute Myeloid Leukemia: Results from the COG AAML1031 trial. <i>Submitted</i>	111
<b>Chapter 5</b>	Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-kB subunit RelA. <i>Proteomics – Clinical Applications. In press</i>	147
<b>Chapter 6</b>	RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequences. <i>Leukemia. In press</i>	183
<b>Chapter 7</b>	Targeted therapy in acute myeloid leukemia: current status and new insights from a proteomic perspective. <i>Expert Rev Proteomics. 2020;17(1):1-10</i>	221
<b>Chapter 8</b>	Summary, discussion & future perspectives	251
<b>Chapter 9</b>	Dutch summary	271
<b>Chapter 10</b>	Appendices	281

